Stocks · News reference
Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.
Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.
Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.